# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Tria...
Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:TMO) with a Outperform and lowers the price ...
Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:TMO) with a Equal-Weight and lowers the price target ...